FY2025 Earnings Forecast for Alector Issued By William Blair

Alector, Inc. (NASDAQ:ALEC) – Equities researchers at William Blair lifted their FY2025 EPS estimates for shares of Alector in a research note issued on Wednesday, October 22nd. William Blair analyst M. Minter now forecasts that the company will earn ($1.52) per share for the year, up from their prior forecast of ($1.62). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector’s Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.31) EPS.

Alector (NASDAQ:ALEC) last announced its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $7.87 million during the quarter, compared to analyst estimates of $2.76 million. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. Alector has set its FY 2025 guidance at EPS.

A number of other equities research analysts also recently weighed in on the stock. Mizuho set a $1.50 price target on shares of Alector and gave the company a “neutral” rating in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Alector in a report on Wednesday, October 8th. TD Cowen downgraded shares of Alector from a “buy” rating to a “hold” rating in a report on Wednesday. Cowen downgraded shares of Alector to a “hold” rating in a report on Wednesday. Finally, BTIG Research downgraded shares of Alector from a “buy” rating to a “neutral” rating in a report on Wednesday. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Alector currently has an average rating of “Reduce” and an average price target of $3.00.

Alector Stock Performance

Shares of ALEC opened at $1.47 on Friday. The firm has a 50-day moving average price of $2.79 and a 200 day moving average price of $1.88. The firm has a market capitalization of $148.78 million, a PE ratio of -1.27 and a beta of 0.99. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. Alector has a 52-week low of $0.87 and a 52-week high of $6.14.

Insider Activity at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total value of $33,040.00. Following the completion of the transaction, the director directly owned 74,909 shares in the company, valued at $176,785.24. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 9.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. FNY Investment Advisers LLC boosted its holdings in shares of Alector by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company’s stock worth $28,000 after buying an additional 10,000 shares during the period. Prudential Financial Inc. acquired a new position in shares of Alector in the second quarter worth about $30,000. HBK Sorce Advisory LLC acquired a new position in shares of Alector in the third quarter worth about $34,000. CWM LLC boosted its holdings in shares of Alector by 370.7% in the first quarter. CWM LLC now owns 33,643 shares of the company’s stock worth $41,000 after buying an additional 26,495 shares during the period. Finally, Hamilton Lane Advisors LLC acquired a new position in shares of Alector in the third quarter worth about $43,000. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.